The same research group has further expanded their observations regarding EZH2 involvement in resistance to BRAFi and has found that combined treatment of BRAFi-resistant melanoma cell lines with tazemetostat and vemurafenib decreases cell viability, induces cell-cycle arrest and increases apoptosis, and this effect has been linked to the downregulation of polo-kinase 1 (PLK1), a key regulator of cell cycle and proliferation (Uebel et al., 2023). This evidence concerns the gene EZH2 and melanoma.